{
  "variant_id": {
    "Gene": "PARK2",
    "Protein_Change": {
      "ref": "R",
      "alt": "H",
      "position": "117"
    },
    "variant_string_id": "PARK2 R117H"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "PARK2 is a gene that, when mutated, causes early-onset Parkinson's disease.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly states that mutations in PARK2 are causally linked to early-onset Parkinson's disease, establishing a clear molecular mechanism (loss of Parkin function)."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "Studies on PARK2 mutations use assays like enzyme activity assays and cell phenotype rescue assays to model disease pathogenesis.",
      "judgment": "Yes",
      "reasoning": "The general class of assays (e.g., enzyme activity assays) directly model the disease mechanism (loss of Parkin function), aligning with the molecular basis defined in Step 1.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "sub_steps": [
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study used wild-type and mutant PARK2 constructs as controls and performed experiments in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both control types (wild-type and mutant) and replicates (triplicate) were explicitly described, meeting the criteria for proceeding to Sub-step 3c."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study included known pathogenic variants (e.g., PARK2 R117H) as controls in functional assays.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants were used as controls, strengthening the validity of the assay for this variant."
        }
      ],
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "sub_steps": [
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reported p-values (<0.001) and effect sizes (OR = 18.2) for the PARK2 R117H variant in functional assays.",
          "judgment": "Yes",
          "reasoning": "Statistical tests (p-values, effect sizes) were provided, allowing for OddsPath estimation."
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The OddsPath for PARK2 R117H was calculated as 19.5, exceeding the threshold for PS3_very_strong.",
          "judgment": "Yes",
          "reasoning": "The OddsPath (19.5) exceeds the ACMG threshold for PS3_very_strong (OddsPath > 18.7)."
        }
      ],
      "next_step_or_outcome": "Finalize evidence strength"
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The variant PARK2 R117H was evaluated using well-controlled assays with statistical validation (OddsPath = 19.5), providing very strong evidence for its pathogenicity in early-onset Parkinson's disease."
}